This website is for UK Healthcare Professionals only

Expert Perspectives

Clear Horizons TV Q&A Videos

Raising the standard of care via treating to target with early and effective intervention

SKYRIZI efficacy

The simplicity of SKYRIZI dosing and delivery

Managing patients in a post-covid world

How to choose the right treatment for the right patient

SKYRIZI in Psoriatic Arthritis

Dr Laura Savage discusses the results of KEEPsAKE 1 and 2 clinical trials

How SKYRIZI works in a minute

Adverse events should be reported. Reporting forms and information can be found at
https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play
or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

References

  1. SKYRIZI Summary of Product Characteristics.

UK-RISN-220026. Date of preparation: March 2022. 


SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
Some patients may not be suitable for SKYRIZI. You are advised to read the Prescribing Information (which can be found on tab above). Please also refer to the SKYRIZI Summary of Product Characteristics for important information including special warnings/precautions for use and summary of adverse reactions.
Study design information can be found on the Study Design page.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com